Novavax | NVAX - Cost Of Sales


Novavax reported $22.1M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Adma Biologics USD 33.74M 16.65M Mar/2026
Agenus USD 642K 399K Sep/2025
AstraZeneca USD 2.52B 2.73B Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Cassava Sciences USD 3.96M 1.16M Sep/2025
Geron USD 1.69M 386K Mar/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
MannKind USD 34.21M 5.38M Jun/2026
Merck USD 3.14B 200M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 93M 862M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.09B 498M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
TG Therapeutics USD 41.19M 7.68M Jun/2026